Corporate
Baugy, France, March 10, 2025 – ERBC, an international preclinical CRO, announces the unification of all its sister companies under a single brand: ERBC. This strategic move integrates ERBC Baugy, ERBC Pomezia, Voxcan, Oncofactory, Novaxia, and Bioprim under one name, reinforcing ERBC commitment to be a preclinical one-stop-shop as expected by our clients and partners worldwide.
ERBC stands the true partner, offering a unique opportunity to work with a family-sized, agile company that delivers a comprehensive suite of services including safety assessment, pharmacokinetics, bio-analytics, translational models and New Alternative Methodologies (NAM).
By aligning resources, expertise, and capabilities, ERBC offers an unparalleled, client-centric approach designed to meet the evolving challenges of the pharmaceutical, biotech, chemical, and medical device industries.
This evolution brings key advantages:
✅ Seamless Collaboration – The single ERBC brand ensures our partners easy access to our full suite of services, streamlining collaboration and project coordination.
✅ Enhanced Expertise & Innovation – The combined knowledge and advanced technologies of ERBC entities drive scientific and regulatory value, ensuring fast, efficient project execution.
✅ Optimized Client Experience – A unified structure means smooth processes and quick responses, enhancing the overall client experience.
✅ Future-Ready Growth – This integration strengthens ERBC’s ability to adapt quickly and effectively to the evolving needs of clients and partners.
“Unifying our companies under the ERBC name is a statement of our shared vision for preclinical development. By bringing our strengths together, we enhance our ability to support clients with cutting-edge preclinical services under one roof, accelerating the pace of preclinical development. Our close proximity to clients throughout their multiple projects allows us to anticipate their future needs and proactively develop new innovative models and services. As part of one unified team, our clients’ projects become ERBC’s projects, ensuring seamless and longstanding collaboration,” said Christophe Priou, CEO of ERBC.
Clients, partners, and investors can continue to expect the same dedication and expertise that define ERBC. As we move forward, ERBC remains committed to innovation, regulatory excellence, and scientific leadership in preclinical research.
